Epidiolex Epidiolex US, is net that in sales Justin. sales we one $XXX.X all million, $XXX.X which the of. product net In Epidiolex were QX global performance are Thank you, This product proud $XXX.X were of product million. net XXXX exceptionally million. included QX sales
their quarter through many to prescribe fourth Market research interactions physicians echoed more our were These intention conducted and to by Epilepsy American meeting during in high practice. patients an December. during the physician the in and indicated continued dynamics Society satisfaction patients
and families, their with with that patients from Dravet coverage Beyond meeting payer a the having Epidiolex positive and is included this satisfaction feedback LGS high level additional impact of syndrome. and
Epidiolex epilepsy. for ability examples of their to heard We access intractable other also
less than believe our opportunities even see indicated with significant to we successful of still our in market, percent Dravet, that date, and We LGS XX% adoption penetrated the population. many growth XXXX. In in room we for leaving growth for are
of of launch, across in first to terms see normal the in We new a a significant represented a base. AED majority prescriptions. the adoption as a XXXX of therefore specialist wider accelerate concentrated physicians opportunity In year prescriber and number institutions of
A this assistants time, DS and epilepsy nurse on patients base spend a mainly see year LGS wide expanding and and targets effort who patients. spectrum of specialist our and key resources priority to adult solid will neurologists, be of of with physicians, undiagnosed diagnosed practitioners more among consisting physician
delays or of LGS term care segment and in with majority these Dravet of impacted seizures, current team. in facilities term homes many individuals with including is XXXX and to opportunity These We're highly deployment associated care who believe living resources and patients long care in the long of a suffer generally developmental settings service An layer those skilled reside group nursing within additional can to in first dedicated - refractory are be with facilities. that small individuals beginning from these the syndrome. quarter. focused We this
also be of for Epidiolex focal TSC expected launch spectrum of drug's greatly our of peak seizure these generalized and of this potential. types the sales population we year. understanding effectiveness epilepsy We The potential which prepare continue an later expands the treat to both to syndromes, associated important TSC broad an believe Epidiolex, with driver rare will in a
patient promotional population. in this readying excited and materials team begin Our outreach is to
for Finally, Payer a key further in XXXX. coverage already payer priority expansion is XXXX strong. of coverage was
towards lives instance, and of one This of to are means prior move to prescribed authorizations opportunity an reimbursement already there we further by open a prior require an post-launch over of if covered this believe Epidiolex coverage indication open is physician, available a For for to year required lives. is epilepsy portion is XX% no XX% that covered authorization access, access. a
strategies needs coverage, awareness a to developing Epidiolex are Epidiolex, new The As utilization and patient enhancing expand will the could we role communicating access payer coverage focus in access and and of services. patients reimbursement address look support reimbursement accessing place of increase to awareness on that team in putting evolving on of that we Epidiolex. and
our My observations confidence access following comes in from XXXX. to widen to the ability from
strong compliance high, response. patient clinical First, is indicating a
our reassuring written been epileptology neurology for and prescribed Epidiolex payers predominately by Second, prescriptions appropriate patients. by physicians thereby targets, appropriate that has are
Third, use adverse demonstrate associated outcomes to restrictive on Epidiolex utilization impact we Fourth, of that cost impact have costs. and uncontrolled data patient with has management has an medical epilepsy. a on favorable
patients. Fifth, value is of before and reasonable, consistent payers providing the Epidiolex and plan the proposition a what average price considered we guided their with positive launch for
Upon And Overall, Epidiolex Epidiolex finally, patients well for in based position on we to believe often payers rare to Epidiolex treatment other factors want epilepsy we utilize XXXX. physicians no approved treat that know appeal, approve exists. necessity. these medical intractable whom
let on In in expect closing, what me comment we quarter. the upcoming
of have our we we QX may as don't good do full the first medicines. While a experience the that seasonality was Epidiolex other you year launch, comparator, influences see many last expect in quarter
stated at this quarter model as Conference, QX in upcoming of January consistent we expect JPMorgan be As sales you the performance to QX. that we would with
to turn Chris like Chris? update over in an I'd provide call progress Europe. on to to our the Now
